

Confirmed Speakers

Keynote Lecture

Integrative Structural Biology of GPCRs (KL01)



Prof. Kurt WÜTHRICH
(THE SCRIPPS RESEARCH INSTITUTE, USA & ETH ZURICH, Zurich, Switzerland)

Session 1: Hot Topics

Fragment Based Target Screening to Prioritise Novel Antimicrobial Targets (OC05)



Dr Peter CANNING
(LIFEARC, Stevenage, United Kingdom)

Structure of an Essential Inner Membrane Protein-LPS Complex (OC04)



Dr Thomas CLAIRFEUILLE
(GENENTECH, INC., South San Francisco, United States)

High-Throughput, Automated Crystallography Pipelines for Drug Discovery (OC03)



Dr Irina CORNACIU
(EMBL GRENOBLE, Grenoble, France)

Biophysics as a Key Element in the Early Phase of Drug Discovery (IL01)



Dr Matthias FRECH
(MERCK, Darmstadt, Germany)

Fragment Based Screening: Critical Aspects of its Performance and Evaluation Screening a Diverse Set of Cancer Target Classes (OC02)



Dr Andrea GOHLKE
(BEATSON INSTITUTE FOR CANCER RESEARCH, Glasgow, United Kingdom)

The Way Home: Molecular Recognition Path of L-TRP to IDO1 (OC01)



Prof. Antonio MACCHIARULO
(UNIVERSITY OF PERUGIA, Perugia, Italy)

Session 2: X-ray Crystallography ? Cryo-EM Complementarity

Using X-ray and Cryo-EM Approaches to Study Allosteric Regulation of GTP Cyclohydrolase I (OC06)



Dr Rebecca EBENHOCH
(BOEHRINGER INGELHEIM, Biberach, Germany)

Confirmed Speakers

Structural Studies of Chromatin Remodellers by Cryo-EM: Challenges and Opportunities for Drug Development (IL03)



Prof. Karl-Peter HOPFNER
(LUDWIG-MAXIMILIANS UNIVERSITY, München, Germany)

High-Resolution Structure Determination of Dynamic Macromolecular Complexes by Cryo-EM (IL02)



Prof. Holger STARK
(MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY, Göttingen, Germany)

Cryo-EM, a New Tool for Drug Discovery at Novartis (IL04)



Dr Christian WIESMANN
(NOVARTIS, Basel, Switzerland)

Session 3: Chemical Biology Meets Biophysics for Drug Discovery

Biophysical and Structural Principles of PROTAC Mechanism of Action (IL06)



Prof. Alessio CIULLI
(UNIVERSITY OF DUNDEE, Dundee, United Kingdom)

Rational Design of Kinase Inhibitors Using Structure and Biophysical Data (IL07)



Prof. Stefan KNAPP
(GOETHE UNIVERSITY FRANKFURT, Frankfurt am Main, Germany)

Illuminating the Path to New E3-Ligases for Targeted Protein Degradation (IL05)



Ms Hannah LITHGOW
(UNIVERSITY OF STRATHCLYDE & GSK, Glasgow, United Kingdom)

(BIOIB,RICA)

The Development and Biophysical Characterisation of Click-Tagged, Reversible Probes to Measure Target Occupancy of ERK1/2 Kinase Inhibitors (OC07)



Dr Chiara Rosa VALENZANO
(ASTEX PHARMACEUTICALS, Cambridge, United Kingdom)

The PROTAC Design Toolbox: Biophysically Enabling the Optimisation of a Potent SMARCA Degradator (OC08)



Dr David ZOLLMAN
(UNIVERSITY OF DUNDEE, Dundee, United Kingdom)

Confirmed Speakers

Session 4: MS-Based Methods

Identifying an Escape Route from Adverse Effects of the Liver X Receptor Ligands Using HDX-MS (OC09)



Dr Anna BELORUSOVA
(ASTRAZENECA, Molndal, Sweden)

Advances in Structural Mass Spectrometry for Drug Discovery and Therapeutic Protein Characterization (IL08)



Dr Sarah CIANFERANI
(UNIVERSITY OF STRASBOURG, Strasbourg, France)

Use of Mass Spectrometry in Small Molecule Lead Discovery (IL10)



Dr Jörg HOERNSCHEMEYER
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

Sugars in the Gas Phase? Novel Techniques to Unravel the Glycocode (IL09)



Prof. Kevin PAGEL
(FREIE UNIVERSITÄT BERLIN, Berlin, Germany)

Session 5: Characterisation of Small Molecules Binding to RNA

Structural Basis for Gene-Specific RNA Splicing Correction Induced by a Small Molecule (IL12)



Prof. Frédéric ALLAIN
(ETH ZURICH, Zurich, Switzerland)

Hit Discovery for Riboswitch Ligands (IL11)



Prof. Ruth BRENK
(UNIVERSITY OF BERGEN, Bergen, Norway)

Detection of Ligand-Induced Conformational Changes in Oligonucleotides by Second-Harmonic Generation (OC10)



Dr Margaret BUTKO
(BIODESY, South San Francisco, United States)

Ribosomal Translation and Human Diseases (IL13)



Prof. Eric WESTHOF
(INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE, Strasbourg, France)

Confirmed Speakers

Session 6: Enabling Tools for Biophysical and Structural Studies

Impact of Mechanistic Enzymology and Bio-Structural Mass Spectrometry on the Progression of a Serine Hydrolase Inhibitor Discovery Project (OC12)



Dr Mathias ANTOINE
(INSTITUT DE RECHERCHES SERVIER, Croissy-Sur-Seine, France)

Wave-Guided Interferometry and Biophysical Methods Enabling Structure-Based Drug Discovery on Membrane Protein Targets (IL18)



Dr Nicolas BOCQUET
(LEADXPAG AG, Villigen, Switzerland)

An Integrated Molecular-Scale Biophysics Approach to Drug Discovery: the Contribution of the ARBRE-MOBIEU European Network (IL17)



Dr Patrick ENGLAND
(INSTITUT PASTEUR, Paris, France)

New Biophysical Approaches to Study IRES RNA/Ribosomes Interactions (OC11)



Dr Eric ENNIFAR
(CNRS, Strasbourg, France)

Strategies to Enable Challenging Biophysical and Structural Studies (IL15)



Dr Stefan GESCHWINDNER
(ASTRAZENECA, Mölndal, Sweden)

SPR-Based Approaches to Enable Direct Binding Assays for Membrane Proteins (IL16)



Dr Sylwia HUBER
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

Innovating Drug Discovery by Locking GPCRs in Functional Conformations (IL14)



Dr Christel MENET
(CONFO THERAPEUTICS, Brussels, Belgium)